Skip to main content

Table 1 Comparison of demographic data between the 2 groups. Numbers indicate median (25th-75th interquartile range)

From: The use of cell salvage during second-stage reimplantation for the treatment of chronic hip periprosthetic joint infection: a retrospective cohort study

Variables

Cell salvage reinfused group

Control group

P-Value

(n = 61)

(n = 64)

Gender, male n (%)

32 (52.5)

48 (75.0)

0.221b

Age at reimplantation (year)

59.0 (49.5–70.0)

56.0 (45.3–69.0)

0.527a

BMI (kg/m2)

24.7 (21.9–26.5)

24.1 (22.0–27.5)

0.947a

ASA classification, n (%)

  

0.568b

 I–II

39 (63.9)

45 (70.3)

 

 III

22 (36.1)

19 (29.7)

 

Charlson comorbidity index, n (%)

  

0.342b

 1–2

16 (26.2)

22 (34.4)

 

 3–5

27 (44.3)

30 (46.9)

 

 ≥ 6

18 (29.5)

12 (18.8)

 

Comorbidities, n (%)

 Diabetes mellitus

7 (11.5)

10 (15.6)

0.605b

 Inflammatory arthritis

4 (6.6)

6 (9.4)

0.744b

 Chronic hepatitis

3 (4.9)

5 (7.8)

0.718b

 Chronic anemia

8 (13.1)

11 (9.4)

0.622b

Tobacco use, n (%)

19 (31.1)

28 (43.8)

0.196b

Alcoholism, n (%)

21 (34.4)

25 (39.1)

0.711b

Resistant strain, n (%)

6 (9.8)

6 (9.4)

1.000b

Positive culture, n (%)

16 (26.2)

19 (29.7)

0.695b

McPherson host type, n (%)

  

0.865b

 A

24 (39.3)

27 (42.2)

 

 B

25 (41.0)

27 (42.2)

 

 C

12 (19.7)

10 (15.6)

 

Components revised, n (%)

  

0.380b

 Acetabular component

4 (6.6)

2 (3.1)

 

 Femoral component

0 (0.0)

2 (3.1)

 

 Dual components

57 (93.4)

60 (93.8)

 

Time of antibiotic administration (week)

Spacer stage duration (mo)

6.0 (4.5–11.0)

7.0 (5.0–11.8)

0.630a

Follow-up (mo)

70.0 (54.5–94.0)

75.0 (46.3–84.8)

0.592a

Failure after reimplantation, n (%)

1 (1.6)

3 (4.7)

0.330c

  1. ASA American Society of Anesthesiologists, BMI body mass index
  2. aThe Mann–Whitney U test
  3. bThe Fisher exact test
  4. cThe log-rank test